Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 10, 2006, Pages 2628-2631

  Wang, Shudong ^a   Zhelev, Nikolai Z ^a   Duff, Susan ^a   Fischer, Peter M ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

Antitumour activity; Cell delivery vector; Drug peptide conjugate; Paclitaxel; Penetratin

Indexed keywords

DRUG CARRIER; PACLITAXEL; PACLITAXEL DERIVATIVE; PENETRATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONJUGATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STABILITY; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; HALF-LIFE; HUMANS; MOLECULAR SEQUENCE DATA; PACLITAXEL; STRUCTURE-ACTIVITY RELATIONSHIP;

MINK CELL FOCUS-FORMING VIRUS;

EID: 33645868648     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.02.035     Document Type: Article

References (32)

1. Le Roux I., Joliot A.H., Bloch-Gallego E., Prochiantz A., and Volovitch M. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 9120
2. Derossi D., Joliot A.H., Chassaing G., and Prochiantz A. J. Biol. Chem. 269 (1994) 10444
3. Derossi D., Chassaing G., and Prochiantz A. Trends Cell Biol. 8 (1998) 84
4. Allinquant B., Hantraye P., Mailleux P., Moya K., Buillot C., and Prochiantz A. J. Cell Biol. 128 (1995) 919
5. Joliot A., Pernelle C., Deagostini-Bazin H., and Prochiantz A. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 1864
6. Rousselle C., Clair P., Lefauconnier J.-M., Kaczorek M., Scherrmann J.-M., and Temsamani J. Mol. Pharmacol. 57 (2000) 679
7. Rousselle C., Smirnova M., Clair P., Lefauconnier J.-M., Chavanieu A., Calas B., Scherrmann J.-M., and Temsamani J. J. Pharmacol. Exp. Ther. 296 (2001) 124
8. Mazel M., Clair P., Rousselle C., Vidal P., Scherrmann J.M., Mathieu D., and Temsamani J. Anti-Cancer Drugs 12 (2001) 107
9. Fischer P.M., Zhelev N.Z., Wang S., Melville J.E., Fåhraeus R., and Lane D.P. J. Pept. Res. 55 (2000) 163
10. Fischer, P. M.; Wang, S. PCT Int. Patent Appl. Publ. WO 2000/01417, 2000, Cyclacel Limited, Dundee, Scotland, UK.
11. Fischer, P. M.; Wang, S.; Zhelev, N. Z. U.S. Patent 6,472,507, 2002, Cyclacel Limited.
12. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. J. Am. Chem. Soc. 93 (1971) 2325
13. Cragg G.M. Med. Res. Rev. 18 (1998) 315
14. Hortobagyi G.N. Semin. Oncol. 22 (1995) 101
15. Schiff P.B., Fant J., and Horwitz S.B. Nature 277 (1979) 665
16. Wall M.E., and Wani M.C. J. Ethnopharmacol. 51 (1996) 239
17. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. J. Med. Chem. 39 (1996) 424
18. Greenwald R.B., Pendri A., and Bolikal D. J. Med. Chem. 60 (1995) 331
19. Deutsch H.M., Glinski J.A., Hernandez M., Haugwitz R.D., Narayanan V.L., Suffness M., and Zalkow L.H. J. Med. Chem. 32 (1989) 788
20. Terwogt J.M., Nuijen B., Huinink W.W., and Beijnen J.H. Cancer Treat. Rev. 23 (1997) 87
21. Ferguson M.J., Ahmed F.Y., and Cassidy J. Drug Resist. Updat. 4 (2001) 225
22. Liu C., Strobl J.S., Bane S., Schilling J.K., McCracken M., Chatterjee S.K., Rahim-Bata R., and Kingston D.G.I. J. Nat. Prod. 67 (2004) 152
23. Denis J.N., Greene A.E., Serra A.A., and Luche M.J. J. Org. Chem. 51 (1986) 46
24. Haselsberger K., Peterson D.C., Thomas D.G., and Darling J.L. Anti Cancer Drugs 7 (1996) 331
25. Mellado W., Magri N.F., Kingston D.G., Garcia-Arenas R., Orr G.A., and Horwitz S.B. Biochem. Biophys. Res. Commun. 124 (1984) 329
26. Mathew A., Mejillano M., Nath J., Himes R., and Stella V. J. Med. Chem. 35 (1992) 145
27. Greenwald R.B., Pendri A., Bolikal D., and Gilbert C.W. Bioorg. Med. Chem. Lett. 4 (1994) 2465
28. Fischer P.M., Krausz E., and Lane D.P. Bioconjugate Chem. 12 (2001) 825
29. Nicolaou K.C., Riemer C., Kerr M.A., Rideout D., and Wrasidlo W. Nature 364 (1993) 464
30. Belmont L.D., and Mitchison T.J. Cell 84 (1996) 623
31. McMeekan J., and Wadsworth P. BioTechniques 24 (1998) 870
32. 2 requires 3354.9).